The changing landscape of medicare part D coverage: effects of the Inflation Reduction Act (IRA) in dermatology

Medicare Part D holds an important role in facilitating prescription drug coverage for older adults in the United States seeking dermatologic treatment. With the aim to ensure improved healthcare access for its beneficiaries, this optional plan presents distinct challenges when compared to commercial insurance due to its unique legislative regulations. Notably, the Anti-Kickback Statute hinders Medicare beneficiaries from using manufacture coupons or discounts, a practice commonly employed by commercial insurance patients. Consequently, older adults with Medicare encounter much higher retail prices for certain medications, limiting access and further exacerbating healthcare disparities. Recent legislative efforts, notably the Inflation Reduction Act (IRA), aim to mitigate these challenges, allowing direct Medicare negotiations with manufacturers and introducing an annual cap on out-of-pocket expenses. However, these changes may have unintended consequences, including premium increases and provider opt-outs. Physicians, including dermatologists, must stay informed about evolving policies, advocate for their patients and actively engage in healthcare reform to ensure equitable access to dermatologic care for older adults.